Focused Ultrasound Hyperthermia for Targeted Drug Release from Thermosensitive Liposomes: Results from a Phase I Trial

Abstract

To demonstrate the feasibility and safety of using focused ultrasound planning models to determine the treatment parameters needed to deliver volumetric mild hyperthermia for targeted drug delivery without real-time thermometry. Materials and Methods: This study was part of the Targeted Doxorubicin, or TARDOX, phase I prospective trial of focused ultrasound-mediated, hyperthermia-triggered drug delivery to solid liver tumors (ClinicalTrials.gov identifier NCT02181075). Ten participants (age range, 49-68 years; average age, 60 years; four women) were treated from March 2015 to March 2017 by using a clinically approved focused ultrasound system to release doxorubicin from lyso-thermosensitive liposomes. Ultrasonic heating of target tumors (treated volume: 11-73 cm 3 [mean 6 standard deviation, 50 cm 3 6 26]) was monitored in six participants by using a minimally invasive temperature sensor; four participants were treated without real-time thermometry. For all participants, CT images were used with a patient-specific hyperthermia model to define focused ultrasound treatment plans. Feasibility was assessed by comparing model-prescribed focused ultrasound powers to those implemented for treatment. Safety was assessed by evaluating MR images and biopsy specimens for evidence of thermal ablation and monitoring adverse events. Results: The mean difference between predicted and implemented treatment powers was 20.1 W 6 17.7 (n = 10). No evidence of focused ultrasound-related adverse effects, including thermal ablation, was found. Conclusion: In this 10-participant study, the authors confirmed the feasibility of using focused ultrasound-mediated hyperthermia planning models to define treatment parameters that safely enabled targeted, noninvasive drug delivery to liver tumors while monitored with B-mode guidance and without real-time thermometry. Pubished under a CC BY 4.0 license.

Polar Lipid Fraction E from Sulfolobus acidocaldarius and Dipalmitoylphosphatidylcholine Can Form Stable yet Thermo-Sensitive Tetraether/Diester Hybrid Archaeosomes with Controlled Release Capability

“…In addition, hyperthermia improves blood flow and permeability near tumor vessels, increasing nanoparticle extravasation [14,17]. Several thermo-sensitive liposomes have been formulated to attain maximum drug release in response to hyperthermia treatment [18][19][20][21][22][23][24][25][26][27][28][29]. One thermo-sensitive liposome currently in phase III clinical trials is ThermoDox.…”

<p>Smart Targeting To Improve Cancer Therapeutics</p>

“…182,183 In a recent study, the trial demonstrated that the ThermoDox ® , designed to release targeted levels of doxorubicin into and around tumors with heat and ultrasound activation, increased doxorubicin delivery to tumors in the majority of liver cancer patients in a 10-patient trial. 184 In addition, photodynamic therapy (PDT) is a novel noninvasive medical application that utilizes a photosensitizing agent (PS) to kill pathological cells. The PS is a chromophore normally derived from porphyrins which absorbs light and then produces reactive oxygen species (ROS) that kill targeted cells.…”

Ultrasound-Mediated Drug Delivery in Cancer Therapy: A Review

“…In another study, Gray et al [62] conducted a phase I trial study involving focused US-mediated hyperthermiatriggered drug delivery to solid liver tumors. The ten participants were treated from March 2015 to March 2017 using a clinically approved focused US system to release DOX from thermo-sensitive liposomes.…”